Medical equipment manufacturer Boston Scientific Corporation has agreed to acquire US-based thrombectomy platform developer Devoro Medical for $269m.
Devoro Medical’s WOLF platform removes blood clots like deep vein thrombosis, peripheral artery occlusions or pulmonary embolisms through prongs inserted into veins or arteries.
Boston Scientific already owns a 16% stake in Devoro stemming from a strategic investment in 2019, when Devoro Medical raised approximately $8.5m in August from 16 unnamed investors according to a regulatory filing.
The latest deal involves the corporate purchasing the remaining 84% and comes with up to $67m in contingent payments if certain clinical and regulatory milestones are achieved.
Jeff Mirviss, president of peripheral interventions at Boston Scientific, said: “The addition of the WOLF platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies.
“Clot management remains a core focus of our business, and upon commercialisation, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic Endovascular System and the AngioJet Thrombectomy System.”
